Patent · US Active

Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

US10533056B2 · kind B2 · utility

3Cited by

0References

64Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Bin Liu · Fishers, US
Yang Su · South San Francisco, US
Scott Bidlingmaier · San Francisco, US
Christopher R. Behrens · San Francisco, US
Namkyung Lee · San Francisco, US

Key dates

Filing date	Sep 10, 2015
Grant date	Jan 14, 2020
Priority date	—
Expiry date	Oct 17, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and/or therapeutic targeting of CD46-overexpressing tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.